PreComb’s proprietary 3DTwin® technology combines fully automated and clinically relevant drug testing with patient-derived biological tumor twins, AI-guided data analysis and response prediction. It is tailored to be implemented directly in the clinic for oncology research and precision medicine.
Together, we aim to advance personalized oncology for the best possible patient benefit.